Lack of effect of long-term octreotide therapy in severe thyroid-associated dermopathy

Thyroid

Volumn 13, Issue 5, 2003, Pages 465-470

  Rotman Pikielny, Pnina ^a   Brucker Davis, Françoise ^b   Turner, Maria L ^c   Sarlis, Nicholas J ^a   Skarulis, Monica C ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY HOSPITAL OF NICE   (France)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FLUOCINONIDE; LEVOTHYROXINE; OCTREOTIDE; PENTETREOTIDE; PENTETREOTIDE IN 111; SOMATOMEDIN C; SOMATOSTATIN; THIAMAZOLE;

ADULT; ARTICLE; BODY MASS; CASE REPORT; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; GRAVES DISEASE; HUMAN; LONG TERM CARE; LYMPHEDEMA; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; SELF REPORT; SKIN DISEASE; SKIN EXAMINATION; THYROID ASSOCIATED DERMOPATHY; THYROID FUNCTION; WEIGHT REDUCTION;

ADULT; ANTHROPOMETRY; BODY MASS INDEX; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAVES DISEASE; HUMANS; LEG DERMATOSES; MIDDLE AGED; MYXEDEMA; OCTREOTIDE; THYROTROPIN; THYROXINE; TREATMENT OUTCOME;

EID: 0038543394     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/105072503322021124     Document Type: Article

References (25)

1. Fatourechi V, Pajouhi M, Fransway AF 1994 Dermopathy of Graves disease (pretibial myxedema). Review of 150 cases. Medicine 73:1-7.
2. Smith TJ, Bahn RS, Gorman CA 1989 Connective tissue, glycosaminoglycans, and diseases of the thyroid. Endocr Rev 10:366-391.
3. Bull RH, Coburn PR, Mortimer PS 1993 Pretibial myxoedema: A manifestation of lymphoedema? Lancet 341:403-404.
4. Korducki JM, Loftus SJ, Bahn RS 1992 Stimulation of glycosaminoglycan production in cultured human retroocular fibroblasts. Invest Ophthalmol Vis Sci 33:2037-2042.
5. Hansson HA, Petruson B, Skottner A 1986 Somatomedin C in pathogenesis of malignant exophthalmos of endocrine origin. Lancet 1:218-219.
6. Imai Y, Odajima R, Inoue Y, Shishiba Y 1992 Effect of growth factors on hyaluronan and proteoglycan synthesis by retroocular tissue fibroblasts of Graves' ophthalmopathy in culture. Acta Endocrinol (Copenh) 126:541-552.
7. Pasquali D, Vassallo P, Esposito D, Bonavolonta G, Bellastella A, Sinisi AA 2000 Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves' ophthalmopathy. J Mol Endocrinol 25:63-71.
8. Chang TC, Kao SC, Huang KM 1992 Octreotide and Graves' ophthalmopathy and pretibial myxoedema. BMJ 304:158.
9. Kriss JP, Pleshakov V, Rosenblum A, Sharp G 1967 Therapy with occlusive dressings of pretibial myxedema with fluocinolone acetonide. J Clin Endocrinol Metab 27:595-604.
10. Kriss JP 1987 Pathogenesis and treatment of pretibial myxedema. Endocrinol Metab Clin North Am 16:409-415.
11. Benoit FL, Greenspan FS 1967 Corticoid therapy for pretibial myxedema. Observations on the long-acting thyroid stimulator. Ann Intern Med 66:711-720.
12. Kuzuya N, DeGroot LJ 1982 Effect of plasmapheresis and steroid treatment on thyrotropin binding inhibitory immunoglobulins in a patient with exophthalmos and a patient with pretibial myxedema. J Endocrinol Invest 5: 373-378.
13. Antonelli A, Navarranne A, Palla R, Alberti B, Saracino A, Mestre C, Roger P, Agostini S, Baschierri L 1994 Pretibial myxedema and high-dose intravenous immunoglobulin treatment. Thyroid 4:399-408.
14. Tsuzaki S, Moses AC 1990 Somatostatin inhibits deoxyribonucleic acid synthesis induced by both thyrotropin and insulin-like growth factor-I in FRTL5 cells. Endocrinology 126:3131-3138.
15. Lichtenauer-Kaligis EG, van Hagen PM, Lamberts SW, Hofland LJ 2000 Somatostatin receptor subtypes in human immune cells. Eur J Endocrinol 143(Suppl 1):S21-S25.
16. Postema PT, Krenning EP, Wijngaarde R, Kooy PP, Oci HY, van den Bosch WA, Reubi JC, Wiersinga WM, Hooijkaas H, van der Loos T, et al. 1994 [111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: A parameter for disease activity? J Clin Endocrinol Metab 79:1845-1851.
17. Krassas GE, Dumas A, Pontikides N, Kaltsas T 1995 Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol (Oxf) 42:571-580.
18. Kuyvenhoven JP, van der Pijl JW, Goslings BM, Wiersinga WM 1996 Graves' dermopathy: Does octreotide scintigraphy predict the response to octreotide treatment? Thyroid 6:385-389.
19. McGregor AM, Petersen MM, McLachlan SM, Rooke P, Smith BR, Hall R 1980 Carbimazole and the autoimmune response in Graves' disease. N Engl J Med 303:302-307.
20. Totterman TH, Karlsson FA, Bengtsson M, Mendel-Hartvig I 1987 Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves' disease. N Engl J Med 316:15-22.
21. Kuroda K, Utani A, Hamasaki Y, Shinkai H 2001 Up-regulation of putative hyaluronan synthase mRNA by basic fibroblast growth factor and insulin-like growth factor-1 in human skin fibroblasts. J Dermatol Sci 26:156-160.
22. Heufelder AE, Bahn RS, Boergen KP, Scriba PC 1993 Detection, localization and modulation of hyaluronic acid/CD44 receptor expression in patients with endocrine orbitopathy [in German]. Med Klin 88:181-184.
23. Cardinale V (ed). Drug Topics Red Book. 2001 Medical Economics, Montvale, NJ.
24. Rapoport B, Alsabeh R, Aftergood D, McLachlan SM 2000 Elephantiasic pretibial myxedema: Insight into and a hypothesis regarding the pathogenesis of the extrathyroidal manifestations of Graves' disease. Thyroid 10:685-692.
25. Shinohara M, Hamasaki Y, Katayama I 2000 Refractory pretibial myxoedema with response to intralesional insulin-like growth factor 1 antagonist (octreotide): Downregulation of hyaluronic acid production by the lesional fibroblasts. Br J Dermatol 143:1083-1086.